Metabolomic Signatures in Doxorubicin-Induced Metabolites Characterization, Metabolic Inhibition, and Signaling Pathway Mechanisms in Colon Cancer HCT116 Cells
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- METABOLITES12(11) · #1047 · 2022
- 피인용
- Web of Science 9Scopus 8
- FWCI (Scopus)
- 0.46
- JCR IF
- JCR 2021 5.581
- ISSN
- 2218-1989
저자
- 가네산라자제1저자교신저자Pusan Natl Univ, Dept Biological Sci, Busan, South Korea
- Prabhakaran, Vasantha-SrinivasanSaveetha Inst Med &Sci SIMATS, Saveetha Sch Engn, Dept Bioinformat, Chennai 602105, India
- Valsala Gopalakrishnan, Abilash교신저자Vellore Inst Technol VIT, Sch Biosci & Technol, Dept BioMed Sci, Vellore 632014, India
초록
Doxorubicin (DOX) is a chemotherapeutic agent is used for various cancer cells. To characterize the chemical structural components and metabolic inhibition, we applied a DOX to HCT116 colon cancer cells using an independent metabolites profiling approach. Chemical metabolomics has been involved in the new drug delivery systems. Metabolomics profiling of DOX-applied HCT116 colon cancer cellular metabolisms is rare. We used 1 H nuclear magnetic resonance (NMR) spectroscopy in this study to clarify how DOX exposure affected HCT116 colon cancer cells. Metabolomics profiling in HCT116 cells detects 50 metabolites. Tracking metabolites can reveal pathway activities. HCT116 colon cancer cells were evenly treated with different concentrations of DOX for 24 h. The endogenous metabolites were identified by comparison with healthy cells. We found that acetate, glucose, glutamate, glutamine, sn-glycero-3-phosphocholine, valine, methionine, and isoleucine were increased. Metabolic expression of alanine, choline, fumarate, taurine, o-phosphocholine, inosine, lysine, and phenylalanine was decreased in HCT116 cancer cells. The metabolic phenotypic expression is markedly altered during a high dose of DOX. It is the first time that there is a metabolite pool and phenotypic expression in colon cancer cells. Targeting the DOX-metabolite axis may be a novel strategy for improving the curative effect of DOX-based therapy for colon cancer cells. These methods facilitate the routine metabolomic analysis of cancer cells.
키워드
HCT116 cellsdoxorubicincolorectal cancerNMRmetabolomicsmetabolic profilingNMR-SPECTROSCOPYDELIVERY
식별자
- Scopus EID
- 2-s2.0-85141654659
- WoS UID
- 000881162300001



로그인
연구물 목록으로